Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Modus Therapeutics raises £2.9m to support further development of sevuparin for SCD Modus Therapeutics has raised SEK32m (£2.9m) from existing investors KDev Investments, Östersjöstiftelsen and Praktikerinvest to support a phase two study of a sickle cell disease (SCD) drug.
Drug Research > Drug Discovery & Development > News
Versant Ventures launches biotechnology firm Jecure Therapeutics Versant Ventures has launched Jecure Therapeutics, a biotechnology firm focused on the discovery of novel therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis.
Drug Research > Drug Discovery & Development > News X-Chem, Janssen extend inflammatory disease collaboration X-Chem has expanded its collaboration with Janssen Biotech for the discovery of new drug leads for inflammatory disease treatment.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Horizon Discovery signs master service deal with top three global pharmaceutical firm
Horizon Discovery Group has signed a Master Services Agreement (MSA) with a top three global pharmaceutical company, extending support for their drug discovery and development efforts to its full suite of services.
Drug Research > Drug Discovery & Development > News
Daiichi Sankyo to close Japanese research subsidiary
Daiichi Sankyo has decided to further reorganize its R&D structure by closing its Japanese research subsidiary, Asubio Pharma in Kobe by the end of March 2018 after reviewing its global R&D structure to increase R&D productivity.
Drug Research > Drug Discovery & Development > News
FDA plans to not to hold advisory committee meeting for Portola’s betrixaban NDA
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) is not planning to hold an Advisory Committee meeting for Portola Pharmaceuticals' New Drug Application (NDA) for betrixaban.
Drug Research > Drug Discovery & Development > News
Prexton Therapeutics raises €29m in Series B Financing
Prexton Therapeutics has closed a €29m Series B round led by Forbion Capital Partners and Seroba Life Sciences.
Drug Research > Drug Discovery & Development > News
Acticor Biotech raises €1.5m in new funding
Acticor Biotech, a bio-pharmaceutical company focused on the treatment of acute ischemic stroke, has raised €1,5m from CapDecisif Management.
Drug Research > Drug Discovery & Development > News
Chondrial Therapeutics secures $22.6m in Series A financing
Biotechnology company Chondrial Therapeutics, focused on the treatment of rare mitochondrial diseases, has secured up to $22.6m in Series A financing led by Deerfield Management besides naming a new president and CEO in Carole Ben-Maimon, MD.
Drug Research > Drug Discovery & Development > News
Portola Pharma assigns AndexXa royalties to HealthCare Royalty Partners
Portola Pharmaceuticals has sold the royalty rights to AndexXa (andexanet alfa) to HealthCare Royalty Partners (HCR) for up to $150m.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests